Want to see KR:214390 full AI Analyst Report?
Kyongbo Pharmaceutical Co., Ltd. (214390) Financial Statements
Kyongbo Pharmaceutical Co., Ltd. Financial Overview
Kyongbo Pharmaceutical Co., Ltd.'s market cap is currently ₩121.21B. The company's EPS TTM is ₩208.03; its P/E ratio is 114.83; and it has a dividend yield of 0.97%. Kyongbo Pharmaceutical Co., Ltd. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ₩ 264.10B | ₩ 238.56B | ₩ 216.36B | ₩ 196.26B | ₩ 170.66B |
| Gross Profit | ₩ 97.82B | ₩ 82.42B | ₩ 63.08B | ₩ 44.42B | ₩ 33.13B |
| Operating Income | ₩ 3.52B | ₩ 10.45B | ₩ 5.54B | ₩ 1.39B | ₩ -6.62B |
| EBITDA | ₩ 16.72B | ₩ 21.60B | ₩ 17.24B | ₩ 12.99B | ₩ 4.21B |
| Net Income | ₩ 182.29M | ₩ 4.64B | ₩ 2.97B | ₩ 610.59M | ₩ -7.50B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ₩ 8.05B | ₩ 6.13B | ₩ 5.35B | ₩ 7.22B | ₩ 4.29B |
| Total Assets | ₩ 319.24B | ₩ 283.89B | ₩ 266.31B | ₩ 240.54B | ₩ 236.98B |
| Total Debt | ₩ 126.67B | ₩ 91.43B | ₩ 75.94B | ₩ 64.51B | ₩ 56.59B |
| Net Debt | ₩ 119.44B | ₩ 87.30B | ₩ 71.46B | ₩ 58.16B | ₩ 52.30B |
| Total Liabilities | ₩ 173.80B | ₩ 137.73B | ₩ 121.92B | ₩ 96.84B | ₩ 91.28B |
| Stockholders' Equity | ₩ 145.44B | ₩ 146.15B | ₩ 144.38B | ₩ 143.70B | ₩ 145.70B |
| Cash Flow | |||||
| Free Cash Flow | ₩ -34.08B | ₩ -13.03B | ₩ -6.03B | ₩ -3.06B | ₩ -355.61M |
| Operating Cash Flow | ₩ 7.46B | ₩ 149.12M | ₩ 4.84B | ₩ 10.13B | ₩ 17.97B |
| Investing Cash Flow | ₩ -37.98B | ₩ -14.63B | ₩ -14.27B | ₩ -14.88B | ₩ -16.17B |
| Financing Cash Flow | ₩ 33.76B | ₩ 13.87B | ₩ 7.16B | ₩ 6.59B | ₩ -9.22B |
Currency in KRW
